Aggressive percutaneous transluminal coronary angioplasty (PTCA) as good as stenting:
This article was originally published in Clinica
Conventional wisdom says stenting may reduce restenosis by scaffolding the coronary artery but new data from the Thoraxcenter in Rotterdam, Holland, suggest that it may simply be a function of larger initial dilation. Dr Patrick Serruys, professor of interventional cardiology and director of the cath lab at the Thoraxcenter, says patients given stent-like PTCA - dilation that reduces stenosis by at least 70% - had similar outcomes to stented patients. However a stent-like result is only achieved in about 35% of PTCA patients compared with 87% of those given stents in the Benestent-I trial (see Clinica No 669/70, p 24). Dr Serruys suggested that trials of provisional stenting should compare results to patients with stent-like PTCA results.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.